Investor Overview

Stock Information
Loading data...

Shares outstanding

10,730,210 (as of 11/9/2023)

Press Releases
Nov 14, 2023

— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from...

Oct 24, 2023

— On track to achieve third consecutive year of net product sales growth — — Third consecutive quarter of favorable net product sales- to- sales and marketing expense ratio — — Reduced...

Oct 13, 2023

-- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET -- SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM)...

Sep 27, 2023

-- Padagis Determined They Will Not Challenge the Phexxi Patents -- -- Evofem Has Phexxi Patent Protection Through 2033 -- SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc.,...

Sep 11, 2023

-- Investor withdraws March 2023 Notice of Default -- -- Notes are no longer convertible to shares of common stock, removing potential dilution from the previously-reserved over 240 million shares...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.  

The U.S. contraceptive market was estimated at $8.3 billion as of 2022. Every 1% market share of the 43.3 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". From May 18, 2023, until June 20, 2023, it traded under the ticker symbol "EVFMD," then reverted to the ticker symbol "EVFM".

Featured Event
Latest Financial Results

Q3 2023, Ended September 30, 2023

Earnings Release
10-Q Filing
XBRL